Blood and tissue collection study for several lung and chest cancers
Part of Cancer, Lungs & breathing clinical trials.
This study collects tissue (and follows patients over time) to better understand the natural course of several types of chest cancers. It may help researchers learn which tests and treatments work best in different cancer types.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be age 18 or older.
- You have—or are being clinically suspected to have—one of these cancers: NSCLC, SCLC, pulmonary neuroendocrine tumors, thymic epithelial tumors, or extrapulmonary small cell cancer.
- Your cancer must be confirmed by biopsy/cell sample, or a specialist may be evaluating you as likely to have one of these cancers while more tissue/pathology is obtained.
- You must be able to understand the study and sign written informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tissue samples from people with non-small cell lung cancer (NSCLC) either before or after treatment. It aims to help researchers learn more about how tumors respond, especially in cancers with specific genetic changes or after certain pre-surgery therapies.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This study looks for cancer-related material in blood, urine, and sometimes bone marrow. It may help researchers understand how to detect cancer activity and track it over time using less invasive tests.
This observational study collects information and lab samples from people with extensive-stage small cell lung cancer. It may help researchers understand how patients respond and improve future care, but it usually does not add new treatment for you.
This study looks at biological samples from people diagnosed with lung cancer at age 45 or younger. It may help researchers understand how young lung cancers differ, which could guide future treatments.
This study looks for biological markers (special signs in your body) that could help doctors choose better immune-based treatments for non-small cell lung cancer. Researchers will study your tumor and blood to understand which patients might benefit most from immunotherapy.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.